Xencor (XNCR) Competitors $11.23 -0.28 (-2.43%) Closing price 04:00 PM EasternExtended Trading$11.23 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. AKRO, ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, and APLSShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Akero Therapeutics (AKRO), Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Akero Therapeutics Alvotech Immunovant Viking Therapeutics Rhythm Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Merus Protagonist Therapeutics Apellis Pharmaceuticals Akero Therapeutics (NASDAQ:AKRO) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Does the MarketBeat Community favor AKRO or XNCR? Xencor received 390 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 73.16% of users gave Xencor an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% XencorOutperform Votes50773.16% Underperform Votes18626.84% Which has preferable earnings & valuation, AKRO or XNCR? Xencor has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-11.62Xencor$110.49M7.34-$126.09M-$3.51-3.28 Do analysts rate AKRO or XNCR? Akero Therapeutics currently has a consensus price target of $76.29, indicating a potential upside of 75.05%. Xencor has a consensus price target of $34.38, indicating a potential upside of 198.65%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Xencor 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media favor AKRO or XNCR? In the previous week, Akero Therapeutics had 4 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Akero Therapeutics and 6 mentions for Xencor. Akero Therapeutics' average media sentiment score of 1.39 beat Xencor's score of 0.43 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is AKRO or XNCR more profitable? Akero Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Xencor -232.77%-30.92%-21.74% Which has more volatility & risk, AKRO or XNCR? Akero Therapeutics has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. SummaryXencor beats Akero Therapeutics on 12 of the 16 factors compared between the two stocks. Remove Ads Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$811.02M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-3.607.2023.1619.03Price / Sales7.34226.01386.8193.17Price / CashN/A65.6738.1634.64Price / Book1.056.476.914.33Net Income-$126.09M$141.90M$3.20B$247.06M7 Day Performance-12.80%-3.20%-2.30%-0.37%1 Month Performance-25.07%-5.64%2.86%-3.85%1 Year Performance-47.99%-7.47%10.51%1.27% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.4332 of 5 stars$11.23-2.4%$34.38+206.1%-48.7%$791.29M$110.49M-3.51280AKROAkero Therapeutics4.2598 of 5 stars$44.82+1.5%$76.29+70.2%+78.2%$3.57BN/A-11.9530Insider TradePositive NewsGap UpALVOAlvotech2.0209 of 5 stars$11.31+0.1%$18.00+59.2%-18.3%$3.41B$391.87M-6.111,026Earnings ReportNews CoverageIMVTImmunovant2.4751 of 5 stars$20.02+2.6%$42.90+114.3%-42.2%$3.40BN/A-7.64120VKTXViking Therapeutics4.3106 of 5 stars$29.83-3.4%$97.67+227.4%-68.6%$3.35BN/A-29.8320Analyst ForecastRYTMRhythm Pharmaceuticals4.4103 of 5 stars$52.34+2.7%$69.31+32.4%+28.0%$3.31B$130.13M-12.09140Analyst RevisionSRRKScholar Rock3.9969 of 5 stars$34.72+0.3%$40.86+17.7%+115.9%$3.29B$33.19M-14.77140Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.3203 of 5 stars$35.20+2.1%$72.64+106.4%-21.4%$3.28B$1.04M-9.44210Analyst ForecastMRUSMerus2.3624 of 5 stars$47.22+0.3%$85.31+80.7%+0.2%$3.26B$36.13M-11.9537Analyst ForecastPTGXProtagonist Therapeutics3.6882 of 5 stars$53.01-3.2%$61.22+15.5%+73.6%$3.25B$434.43M19.93120Analyst ForecastPositive NewsAPLSApellis Pharmaceuticals4.3456 of 5 stars$25.11+1.8%$45.53+81.3%-58.5%$3.15B$781.37M-12.37770Positive News Remove Ads Related Companies and Tools Related Companies Akero Therapeutics Alternatives Alvotech Alternatives Immunovant Alternatives Viking Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Scholar Rock Alternatives Crinetics Pharmaceuticals Alternatives Merus Alternatives Protagonist Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XNCR Stock Free XNCR Stock Alerts